About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Tg(Thy1-APPSwDutIowa)BWevn
transgene insertion B, William E Van Nostrand
MGI:3721992
Summary 4 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cx1
Apoetm2(APOE*3)Mae/Apoetm2(APOE*3)Mae
Tg(Thy1-APPSwDutIowa)BWevn/?
involves: 129P2/OlaHsd * C57BL/6 MGI:4355225
cx2
Apoetm3(APOE*4)Mae/Apoetm3(APOE*4)Mae
Tg(Thy1-APPSwDutIowa)BWevn/?
involves: 129P2/OlaHsd * C57BL/6 MGI:4355230
cx3
Nos2tm1Lau/Nos2tm1Lau
Tg(Thy1-APPSwDutIowa)BWevn/?
involves: C57BL/6 MGI:3829507
tg4
Tg(Thy1-APPSwDutIowa)BWevn/0 involves: C57BL/6 MGI:3722063


Genotype
MGI:4355225
cx1
Allelic
Composition
Apoetm2(APOE*3)Mae/Apoetm2(APOE*3)Mae
Tg(Thy1-APPSwDutIowa)BWevn/?
Genetic
Background
involves: 129P2/OlaHsd * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Apoetm2(APOE*3)Mae mutation (2 available); any Apoe mutation (150 available)
Tg(Thy1-APPSwDutIowa)BWevn mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• increased number of neuroreactive microglia in cortex
• decreased number of neuroreactive microglia in thalamic region
• plaque deposition in cortical parenchyma increased 20%
• reduced deposition in cerebral microvasculature
• microglia are tightly associated with parenchymal plaque amyloid
• increased number of neuroreactive astrocytes in cortex
• decreased number of neuroreactive astrocytes in thalamic region

hematopoietic system
• increased number of neuroreactive microglia in cortex
• decreased number of neuroreactive microglia in thalamic region

immune system
• increased number of neuroreactive microglia in cortex
• decreased number of neuroreactive microglia in thalamic region

homeostasis/metabolism
• plaque deposition in cortical parenchyma increased 20%
• reduced deposition in cerebral microvasculature
• microglia are tightly associated with parenchymal plaque amyloid




Genotype
MGI:4355230
cx2
Allelic
Composition
Apoetm3(APOE*4)Mae/Apoetm3(APOE*4)Mae
Tg(Thy1-APPSwDutIowa)BWevn/?
Genetic
Background
involves: 129P2/OlaHsd * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Apoetm3(APOE*4)Mae mutation (3 available); any Apoe mutation (150 available)
Tg(Thy1-APPSwDutIowa)BWevn mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• increased number of neuroreactive microglia in cortex
• decreased number of neuroreactive microglia in thalamic region
• plaque deposition in cortical parenchyma increased 20%
• reduced deposition in cerebral microvasculature
• microglia are tightly associated with parenchymal plaque amyloid
• increased number of neuroreactive astrocytes in cortex
• decreased number of neuroreactive astrocytes in thalamic region

hematopoietic system
• increased number of neuroreactive microglia in cortex
• decreased number of neuroreactive microglia in thalamic region

immune system
• increased number of neuroreactive microglia in cortex
• decreased number of neuroreactive microglia in thalamic region

homeostasis/metabolism
• plaque deposition in cortical parenchyma increased 20%
• reduced deposition in cerebral microvasculature
• microglia are tightly associated with parenchymal plaque amyloid

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
Alzheimer's disease DOID:10652 J:136318




Genotype
MGI:3829507
cx3
Allelic
Composition
Nos2tm1Lau/Nos2tm1Lau
Tg(Thy1-APPSwDutIowa)BWevn/?
Genetic
Background
involves: C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nos2tm1Lau mutation (8 available); any Nos2 mutation (66 available)
Tg(Thy1-APPSwDutIowa)BWevn mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• amyloid beta deposits in the hippocampus, in the subiculum and thalamus (J:132221)
• deposits are observed by 52 weeks of age (J:143551)
• 65% loss of NPY interneurons in the hippocampus
• thinning of the CA3 and subiculum, with a 40% loss of neurons in the CA3 region (J:132221)
• neuronal loss (J:143551)
• 35% loss of neurons in the subiculum (J:132221)
• neuronal loss (J:143551)
• mice show intraneuronal aggregrates of tau
• hyperphosphorylated tau is seen in the brain and in neuronal processes associated with blood vessels
• neuronal loss is observed in hippocampus, subiculum and CA3
• 30% loss of NeuN-immunopositive neurons in the hippocampus, 35% loss in the subiculum, and 40% loss in the CA3 region of the hippocampus
• loss of neuropeptide Y-immunopositive neurons particularly in the CA3 region and in the subiculum
• 30% loss of neurons in the hippocampus
• 50% reduction in neuropeptide Y-immunopositive neurons overall throughout the hippocampus, a 65% reduction in the CA3 region, and 50% reduction in the subiculum

homeostasis/metabolism
• amyloid beta deposits in the hippocampus, in the subiculum and thalamus (J:132221)
• deposits are observed by 52 weeks of age (J:143551)

behavior/neurological
• mice make more errors in the radial-arm water maze than single Tg(Thy1-APPSwDutIowa)BWevn transgenics, especially on subsequent days, indicating slowed learning and/or retrieval of the task
• mice show increased impaired performance on the Barnes maze compared to single Tg(Thy1-APPSwDutIowa)BWevn transgenics

cellular

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
Alzheimer's disease DOID:10652 J:132221




Genotype
MGI:3722063
tg4
Allelic
Composition
Tg(Thy1-APPSwDutIowa)BWevn/0
Genetic
Background
involves: C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Thy1-APPSwDutIowa)BWevn mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• activation of microglial and astrocytes is elevated in cortex
• microglial cells show significantly increased levels of complement proteins C1q, C3 and C4
• over the course of 1 year, progressive and robust accumulation of insoluble amyloid beta-40 and -42 peptides is observed in mouse brains; increase in peptides is first observed at 3 months and increases markedly by 12 months (J:89848)
• soluble and insoluble amyloid beta-40 peptide levels are 10-fold higher than amyloid beta-42 peptide levels (J:89848)
• amyloid beta deposits are observed in the regions of the subiculum, hippocampus, and cortex at ~3 months; by ~6 months deposits become more numerous and appear in the olfactory bulb and thalamic region as well, with deposits throughout most of the forebrain by 12 months (J:89848)
• parenchymal amyloid deposits mainly present as diffuse, plaque-like deposits, with occasional deposits having a more compact structure suggesting a fibrillar nature (J:89848)
• deposits are largely in parenchyma and in diffuse form in cortex (J:124911)
• levels of amyloid beta-40 and -42 peptides are 12- and 14-fold higher in forebrain microvessels than in whole forebrain homogenates at 12 months of age; at ~3 months, levels in vasculature of forebrains is higher than whole forebrain tissue (J:89848)
• vascular amyloid beta accumulation is prominent in the thalamus and subiculum, and increases with age such that 45-55% of vessels are affected at 12 months of age; at ~6 months of age, amyloid beta deposits in and around microvessels in the thalamus and subiculum are observed (J:89848)
• microvascular amyloid beta accumulations are mainly fibrillar (J:89848)
• some arterioles in these brain regions show strong vascular and perivascular amyloid beta depostion, while blood vessel-rich regions like the hippocampal fissure show large accumulations of perivascular amyloid beta (J:89848)
• evidence of microhemorrhage is observed in microvessels with amyloid beta deposits (J:89848)
• microvascular fibrillar amyloid beta accumulation is observed in thalamic and hippocampal regions (J:124911)
• astrocyte numbers and density are enhanced in thalamic and cortical regions where fibrillar amyloid beta deposits are prominent

immune system
• activation of microglial and astrocytes is elevated in cortex
• microglial cells show significantly increased levels of complement proteins C1q, C3 and C4

cardiovascular system
• reduced cerebral blood flow, CBF, response (21% increase) to whisker stimulation is observed relative to controls (38% increase) at 9 months
• with myocardin gene transfer, CBF response drops to 10% in transgenic mice, a decrease of 50%, while it increased to 27% with shSRF gene transfer compared to 19% in shGFP controls

hematopoietic system
• activation of microglial and astrocytes is elevated in cortex
• microglial cells show significantly increased levels of complement proteins C1q, C3 and C4

homeostasis/metabolism
• mutants show decreased clearance of the mutant form of amyloid beta peptides compared to wild-type amyloid beta
• over the course of 1 year, progressive and robust accumulation of insoluble amyloid beta-40 and -42 peptides is observed in mouse brains; increase in peptides is first observed at 3 months and increases markedly by 12 months (J:89848)
• soluble and insoluble amyloid beta-40 peptide levels are 10-fold higher than amyloid beta-42 peptide levels (J:89848)
• amyloid beta deposits are observed in the regions of the subiculum, hippocampus, and cortex at ~3 months; by ~6 months deposits become more numerous and appear in the olfactory bulb and thalamic region as well, with deposits throughout most of the forebrain by 12 months (J:89848)
• parenchymal amyloid deposits mainly present as diffuse, plaque-like deposits, with occasional deposits having a more compact structure suggesting a fibrillar nature (J:89848)
• deposits are largely in parenchyma and in diffuse form in cortex (J:124911)
• levels of amyloid beta-40 and -42 peptides are 12- and 14-fold higher in forebrain microvessels than in whole forebrain homogenates at 12 months of age; at ~3 months, levels in vasculature of forebrains is higher than whole forebrain tissue (J:89848)
• vascular amyloid beta accumulation is prominent in the thalamus and subiculum, and increases with age such that 45-55% of vessels are affected at 12 months of age; at ~6 months of age, amyloid beta deposits in and around microvessels in the thalamus and subiculum are observed (J:89848)
• microvascular amyloid beta accumulations are mainly fibrillar (J:89848)
• some arterioles in these brain regions show strong vascular and perivascular amyloid beta depostion, while blood vessel-rich regions like the hippocampal fissure show large accumulations of perivascular amyloid beta (J:89848)
• evidence of microhemorrhage is observed in microvessels with amyloid beta deposits (J:89848)
• microvascular fibrillar amyloid beta accumulation is observed in thalamic and hippocampal regions (J:124911)

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
Alzheimer's disease DOID:10652 J:89848
cerebral amyloid angiopathy DOID:9246 J:89848





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
09/03/2024
MGI 6.24
The Jackson Laboratory